Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 8/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276205 | 0.87 | NAMPT (0.51) | NAMPTSPRHSD11B1KMT2APROKR1 | |
| SCHEMBL2278465 | 0.82 | NAMPT (0.51) | NAMPTSPRHSD11B1KMT2APROKR1 | |
| SCHEMBL2282259 | 0.79 | NAMPT (0.59) | NAMPTSPRHSD11B1KMT2A | |
| SCHEMBL2277920 | 0.79 | NAMPT (0.51) | NAMPTSPRHSD11B1KMT2APROKR1 | |
| SCHEMBL2282859 | 0.78 | SPR (0.53) | NAMPTSPRHSD11B1PROKR1CCNC | |
| SCHEMBL2283721 | 0.76 | NAMPT (0.58) | NAMPTSPR | |
| SCHEMBL2281994 | 0.76 | SPR (0.54) | NAMPTSPRHSD11B1PROKR1CCNC | |
| SCHEMBL2282124 | 0.76 | NAMPT (0.57) | NAMPTSPRHSD11B1 | |
| SCHEMBL2280231 | 0.76 | NAMPT (0.57) | NAMPTSPRHRH3 | |
| SCHEMBL3469307 | 0.75 | SPR (0.61) | NAMPTSPRHSD11B1PROKR1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | NAMPT 1938/4885SPR 3835/4885HSD11B1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.